Kronik prostatitin epidemiyolojisi ve tedavisi: Mersin deneyimi

Öz

Amaç: Prostatit, erkeklerde pelvik ağrı, idrar sorunları ve cinsel işlev bozukluğuna neden olan yaygın bir rahatsızlıktır. Bakteriyel prostatitin teşhisi ve tedavisi zor olabilir. Bu çalışmada, bakteriyel prostatite ampirik tedavinin yanıtını ve tedavi başarısızlığına yol açan risk faktörlerini göstermeyi amaçladık.
Gereç ve yöntem: Bu çalışmaya, kronik prostatit düşündüren semptomları olan 39 erkek dahil edildi. Araştırmacılar, hastaların semptomlarını, kan testlerini, idrar testlerini, prostat muayenelerini ve görüntüleme çalışmalarını değerlendirdi. Ardından hastalara uygulanan çeşitli antibiyotikler yanıtlarını takip ettiler. Tüm hastalara başlangıçta günde 3 kez intravenöz 4,5 g piperasilin-tazobaktam ve günde 2 kez 100 mg doksisiklin tablet oral yoldan verildi. Hasta bu tedaviden önce ertapenem + doksisiklin kullanmışsa önce piperasilin tazobaktam + doksisiklin denenmiş, yanıt alınamayan hastalarda imipenem + doksisikline geçilmiştir. Sayısı az olmakla birlikte ertapenem ve doksisiklin tedavisine yanıt alınamayan bazı hastalarda, doğrudan imipenem ve doksisiklin kombinasyonuna geçildiği de görülmüştür. Yetersiz yanıt alınan vakalarda, tedavi günde 4 kez 500 mg intravenöz imipenem ve günde 2 kez 100 mg doksisiklin tabletlere çıkarıldı. İki kombinasyon tedavisinin işe yaramadığı durumlarda, hastanın tedavisi günde 3 kez 4 gram fosfomisin disodyum ile değiştirildi.
Bulgular: Erkeklerin çoğunda sık idrara çıkma gibi alt üriner sistem semptomları vardı, ancak bazılarında bakteri kültürü pozitif çıkmadı. Erkeklerin yaklaşık %30'unun tedavi sırasında antibiyotiklerinde değişikliğe ihtiyacı oldu. Alt grup analizi, tedavi grupları arasında tekrarlama ve tedavi değişikliği ihtiyacı açısından anlamlı bir fark olmadığını gösterdi (p=0,666 ve p=0,212). Regresyon analizi, tedavi değişikliği ile PSA seviyesi ve prostat hacmi arasında istatistiksel olarak anlamlı bir ilişki olmadığını göstermiştir (sırasıyla p=0,587 ve p=0,083). Tedavi yanıtının prostat boyutu veya PSA seviyeleriyle bağlantılı olmadığı görülmüştür.
Sonuç: Bakteriyel prostatit, yüksek oranda tedavi başarısızlığı ve tekrarlama ile karakterize karmaşık bir durumdur. Tanı ve tedavi stratejilerini iyileştirmek için daha fazla araştırmaya ihtiyaç vardır.

Anahtar Kelimeler

• Kronik prostatit
• enfeksiyon
• tedavi süresi
• tedavi başarısı

Destekleyen Kurum

yok

Etik Beyan

Mersin Üniversitesi Etik kurulu (05.7.2023/ 454)

Epidemiology and treatment of chronic prostatitis: Mersin experience

Öz

Purpose: Prostatitis is a common condition in men, causing pelvic pain, urinary problems, and sexual dysfunction. Diagnosing and managing of chronic prostatitis can be challenging. In this study we aimed to demonstrate the response of empiric treatment to chronic prostatitis and risk factors to treatment failure.
Materials and methods: A total of 39 male patients diagnosed with chronic prostatitis were included in this study. Patients with a history of unsuccessful oral antibiotic therapy for chronic prostatitis were included in the study, whereas patients with urological malignancy or a history of urological interventions were excluded. Researchers evaluated their symptoms, blood tests, urine tests, prostate exams, and imaging studies. They then treated them with various antibiotics and tracked their response. All patients initially received piperacillin-tazobactam at a dose of 4.5 g three times daily and oral doxycycline at a dose of 100 mg twice daily. If the patient had previously received ertapenem plus doxycycline, piperacillin-tazobactam plus doxycycline was administered first; in patients who did not respond, the treatment was switched to imipenem plus doxycycline. Although the number was small, it was observed that some patients who did not respond to ertapenem and doxycycline therapy were switched directly to the imipenem and doxycycline combination.
In cases of inadequate response, treatment was increased to intravenous imipenem at a dose of 500 mg four times daily combined with oral doxycycline 100 mg twice daily.
In cases where both combination regimens were ineffective, the patient’s treatment was switched to fosfomycin disodium at a dose of 4 g three times daily.
Results: While most men presented with lower urinary tract symptoms such as urinary frequency, only a few had positive urine cultures. About 30% of men needed a change in antibiotics during treatment. The subgroup analysis showed that there was no significant difference in treatment groups in terms of recurrence and need for treatment change (p=0.666 and p=0.212). The regression analysis showed that there was no statistically significant association between treatment change and prostate-specific antigen level and prostate volume (p=0.587 and p=0.083, respectively). Treatment response did not seem to be linked to prostate size or prostate-specific antigen levels.
Conclusion: Chronic prostatitis is a complex condition with a high rate of treatment failure and recurrence. More research is needed to improve diagnosis and treatment strategies.

Anahtar Kelimeler

• Chronic prostatitis
• infection
• treatment duration
• treatment success

Destekleyen Kurum

None

Etik Beyan

Mersin University Ethics Committee (05.7.2023/ 454)

Kaynakça

1. Schaeffer AJ, Wendel EF, Dunn JK, Grayhack JT. Prevalence and significance of prostatic inflammation. J Urol. 1981;125(2):215-219. doi:10.1016/s0022-5347(17)54976-9
2. Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Gao SY, Calhoun EA. Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community. J Urol. 2005;174(6):2319-2322. doi:10.1097/01.ju.0000182152.28519.e7
3. Collins MM, Meigs JB, Barry MJ, Walker Corkery E, Giovannucci E, Kawachi I. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol. 2002;167(3):1363-1366.
4. Singh S, Singh M, Bains L, Sagar T. Candida prostatitis: A rare entity. Trop Doct. 2023;53(2):282-284. doi:10.1177/00494755221147962
5. Nickel JC, Downey JA, Nickel KR, Clark JM. Prostatitis-like symptoms: one year later. BJU Int. 2002;90(7):678-681. doi:10.1046/j.1464-410x.2002.03007.x
6. Gill BC, Shoskes DA. Bacterial prostatitis. Curr Opin Infect Dis. 2016;29(1):86-91. doi:10.1097/QCO.0000000000000222
7. Magri V, Boltri M, Cai T, et al. Multidisciplinary approach to prostatitis. Arch Ital Urol Androl. 2019;90(4):227-248. doi:10.4081/aiua.2018.4.227
8. Kobayashi I, Ikawa K, Nakamura K, et al. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics. J Infect Chemother. 2015;21(8):575-580. doi:10.1016/j.jiac.2015.04.015

9. Su ZT, Zenilman JM, Sfanos KS, Herati AS. Management of Chronic Bacterial Prostatitis. Curr Urol Rep. 2020;21(7):29. doi:10.1007/s11934-020-00978-z
10. Hua LX, Zhang JX, Wu HF, et al. The diagnosis and treatment of acute prostatitis: report of 35 cases. Zhonghua Nan Ke Xue. 2005;11(12):897-899.
11. Çakıroğlu B, Eyyüpoğlu E, Balcı MBC, Hazar Aİ, Uyanık BS, Doğan AN. The Evaluation of procalcitonin levels in chronic prostatitis patients. Nobel Med. 2016;12(2):60-65.
12. Uyanık BS, Cakiroglu B, Gozukucuk R. Predictive values and relationships of serum PSA levels, delta neutrophil index, neutrophil-lymphocyte ratio and other hematological parameters in patients with acute prostatitis. Urologia journal 2024;91(4):775-780. doi:10.1177/03915603241273883
13. Nickel CJ. Inflammatory and Pain conditions of the Male Genitourinary Tract: Prostatitis and Related Pain Conditions, Orchitis, and Epididymitis. Campbell-Walsh Urology. 11th ed. Elsevier; 2016.
14. Prostate inflammation: A brief review - ScienceDirect. Available at: https://www.sciencedirect.com/science/article/pii/S1879522617300374. Accessed October 08, 2024
15. Zegarra Montes LR, Sanchez Mejia AA, Loza Munarriz CA, Celis Gutierrez E. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int Braz J Urol. 2008;34(1):30-40. https://doi.org/10.1590/S1677-55382008000100006
16. Choi YS, Kim KS, Choi SW, et al. Microbiological etiology of bacterial prostatitis in general hospital and primary care clinic in Korea. Prostate Int. 2013;1(3):133-138. Doi:10.12954/PI.13023
17. Kobayashi I, Ikawa K, Nakamura K, et al. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics. J Infect Chemother. 2015;21(8):575-580. doi:10.1016/j.jiac.2015.04.015
18. Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev. 2013;2013(8):CD009071. doi:10.1002/14651858.CD009071.pub2
19. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 2010;50(12):1641-1652. doi:10.1086/652861
20. Urological Infections - Uroweb. Available at: https://uroweb.org/guidelines/urological-infections. Accessed October 08, 2024
21. Denisuik AJ, Lagacé Wiens PR, Pitout JD, et al. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother. 2013;68(Suppl 1):i57-i65. doi:10.1093/jac/dkt027
22. Kandil H, Cramp E, Vaghela T. Trends in antibiotic resistance in urologic practice. Eur Urol Focus. 2016;2(4):363-373. doi:10.1016/j.euf.2016.09.006
23. Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med. 2006;355(16):1690-1698. doi:10.1056/NEJMcp060423
24. Cordes L, Wilmsen M, Calin R, et al. Evidence for antibiotic durations in chronic bacterial prostatitis: a systematic review. CMI Communications. 2026;3:105156. doi:10.1016/j.cmicom.2025.105156
25. Bartoletti R, Cai T, Nesi G, et al. The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study. World J Urol. 2014;32(3):737-742. doi:10.1007/s00345-013-1145-9
26. Schaeffer AJ, Wu SC, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. Journal of Urology. 2005;174(1):161-164. doi:10.1097/01.ju.0000162017.24965.2b